Search results for "PULMONARY"

2021

Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kuhne‐Center for Allergy Rese…

Peri-Partum respiratory management in neuro-muscular disorders (IT-NEUMA-Pregn study): A proposal by an italian panel and a call for an international…

2023

Advances in the management of patients with neuromuscu- lar diseases (NMDs) have improved patient survival1 3 with increasing pregnancies prevalence.4 NMDs have a broad spectrum of presentation and a subgroup of these women are at risk of developing pulmonary complications (PCs) mainly due to respiratory muscle weakness leading to hypoventilation and ineffective cough

Erythropoietin and Its Double Receptors.

2019

Bronchial responsiveness and airway inflammation in trained subjects [9]

2008

A 79-year-old-man with SARS-CoV-2 pneumonia and unusual pulmonary co-infection

2022

Patients with severe COVID-19 are characterized by local and systemic inflammatory responses, which are responsible for severe acute respiratory failure. Systemic corticosteroids have been used to counteract the inflammatory cascade in severe respiratory patients. The beneficial effect of corticosteroids may be counteracted by adverse effects, including delayed viral clearance and increased risk of secondary infection. In this regard, we describe a case of a 79-year-old man admitted to the Emergency Department of the Palermo Hospital (Italy) because of respiratory failure and pneumonia caused by SARS-CoV-2 infection who developed Nocardia otitidiscaviarum infection. This case highlights the…

Sequential use of noninvasive ventilation and high flow nasal therapy after early extubation in chest trauma patients recovering from acute hypoxaemi…

2022

Reducing Rebreathing During Noninvasive Ventilation: Bias Flow or No Bias Flow?

2019

To the Editor : We read with interest the article by Signori et al[1][1] that evaluated CO2 rebreathing during noninvasive ventilation (NIV) via a full face mask connected to a double-limb ventilation circuit with 2 different configurations: (1) a single mask connector directly attached to the Y-

Autocitación: ¿debemos penalizarla?

2014

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquam…

2013

Abstract Objectives The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). Patients and methods In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500mg/m 2 ) and cisplatin (75mg/m 2 ) on Day 1 (21-day cycles) plus weekly cetuximab (400mg/m 2 loading dose, then 250mg/m 2 ) for 4–6 cycles. Non-progressing patients received maintenance therapy consisting of pemetrexed and cetuximab as above until disease progression. All patients received vitamin supplementation, dexameth…

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or me…

2013

Abstract Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this study. This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. Patients and Methods The patients were randomized (1:1) to 2 parallel arms: pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or pemetrexed (500 mg/m2) plus carboplatin (area under the curve 6) day 1 every 3 weeks (maximum, 6 cycles). Progression-free survival (PFS) was the primary objective; secondary objectives included overall survival (OS), 1-year survival, and s…